

**Clinical trial results:****A Phase 3 Randomized, Double-blind, Placebo controlled, Parallel group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)****Summary**

EudraCT number	2017-000573-37
Trial protocol	IE GB DE AT LT CZ NL SK BG GR PL BE ES PT HU EE HR IT RO
Global end of trial date	01 July 2021

Results information

Result version number	v1 (current)
This version publication date	11 January 2022
First version publication date	11 January 2022

Trial information**Trial identification**

Sponsor protocol code	SHP647-303
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03290781
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Shire
Sponsor organisation address	300 Shire Way, Lexington, United States, MA 02421
Public contact	Study Director, Shire, ClinicalTransparency@takeda.com
Scientific contact	Study Director, Shire, ClinicalTransparency@takeda.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 July 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 July 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to evaluate the efficacy of ontamalimab as maintenance treatment of remission, based on composite score of subject reported symptoms and centrally read endoscopy, in subjects with moderate to severe Ulcerative Colitis (UC).

Protection of trial subjects:

This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 (1996) and E6 R2 (2017), EU Directive 2001/20/EC, the principles of the Declaration of Helsinki, as well as other applicable national ethical and legal requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 April 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	30 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Bosnia and Herzegovina: 2
Country: Number of subjects enrolled	Bulgaria: 11
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Colombia: 2
Country: Number of subjects enrolled	Croatia: 10
Country: Number of subjects enrolled	Czechia: 12
Country: Number of subjects enrolled	Estonia: 1
Country: Number of subjects enrolled	Hungary: 16
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Israel: 3
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Japan: 18
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Lebanon: 1

Country: Number of subjects enrolled	Lithuania: 3
Country: Number of subjects enrolled	Mexico: 8
Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	New Zealand: 2
Country: Number of subjects enrolled	Poland: 95
Country: Number of subjects enrolled	Portugal: 8
Country: Number of subjects enrolled	Romania: 6
Country: Number of subjects enrolled	Russian Federation: 27
Country: Number of subjects enrolled	Slovakia: 9
Country: Number of subjects enrolled	South Africa: 6
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Ukraine: 38
Country: Number of subjects enrolled	United Kingdom: 2
Country: Number of subjects enrolled	United States: 48
Worldwide total number of subjects	366
EEA total number of subjects	198

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	5
Adults (18-64 years)	336
From 65 to 84 years	25
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 400 sites from 4 April 2018 (first subject first visit) to 1 July 2021 (last subject last visit). A total of 366 subjects were enrolled, randomised and received study treatment.

Pre-assignment

Screening details:

Subjects with moderate to severe UC who achieved a clinical response and completed their treatment period in the induction studies (either SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) were re-randomised into this study as ontamalimab and placebo responders to receive placebo or ONTA 25 milligrams (mg) or 75 mg.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	ONTA 25mg/Placebo

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52 in this study.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Arm title	ONTA 25mg/ONTA 25mg
------------------	---------------------

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab
Investigational medicinal product code	SHP647
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Arm title	ONTA 75mg/Placebo
------------------	-------------------

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Arm title	ONTA 75mg/ONTA 75mg
------------------	---------------------

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab
Investigational medicinal product code	SHP647
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Arm title	Placebo/Placebo
------------------	-----------------

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Arm title	Placebo/ONTA 25mg
------------------	-------------------

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ontamalimab
Investigational medicinal product code	SHP647
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Arm title	Placebo/ONTA 75mg
------------------	-------------------

Arm description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab
Investigational medicinal product code	SHP647
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subject received 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Number of subjects in period 1	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo
Started	73	71	86
Completed	24	53	30
Not completed	49	18	56
Adverse event, serious fatal	-	-	1
Consent withdrawn by subject	6	5	9
Disease Relapse	32	5	38
Physician decision	-	1	-
Adverse event, non-fatal	5	7	4
Protocol Deviation	2	-	-
Site Terminated by Sponsor	1	-	2
Unspecified	3	-	2
Lost to follow-up	-	-	-

Number of subjects in period 1	ONTA 75mg/ONTA 75mg	Placebo/Placebo	Placebo/ONTA 25mg
Started	82	11	22
Completed	59	6	19
Not completed	23	5	3
Adverse event, serious fatal	-	1	-
Consent withdrawn by subject	10	1	2
Disease Relapse	7	3	1

Physician decision	-	-	-
Adverse event, non-fatal	1	-	-
Protocol Deviation	1	-	-
Site Terminated by Sponsor	1	-	-
Unspecified	2	-	-
Lost to follow-up	1	-	-

Number of subjects in period 1	Placebo/ONTA 75mg
Started	21
Completed	17
Not completed	4
Adverse event, serious fatal	-
Consent withdrawn by subject	-
Disease Relapse	4
Physician decision	-
Adverse event, non-fatal	-
Protocol Deviation	-
Site Terminated by Sponsor	-
Unspecified	-
Lost to follow-up	-

Baseline characteristics

Reporting groups

Reporting group title	ONTA 25mg/Placebo
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52 in this study.	
Reporting group title	ONTA 25mg/ONTA 25mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	ONTA 75mg/Placebo
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	ONTA 75mg/ONTA 75mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	Placebo/Placebo
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	Placebo/ONTA 25mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	Placebo/ONTA 75mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	

Reporting group values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo
Number of subjects	73	71	86
Age Categorical Units: Subjects			
Age continuous Units: years arithmetic mean	43.3	41.2	42.0

standard deviation	± 15.40	± 13.17	± 13.81
--------------------	---------	---------	---------

Gender categorical Units: Subjects			
Female	27	29	35
Male	46	42	51
Ethnicity Units: Subjects			
Hispanic or Latino	6	6	4
Not Hispanic or Latino	67	64	82
Not Reported	0	1	0
Unknown	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	2	0	1
Asian	5	4	5
Black or African American	3	1	2
White	58	62	77
Native Hawaiian or Other Pacific Islander	1	0	0
More than one race	4	2	0
Unknown or Not Reported	0	2	1

Reporting group values	ONTA 75mg/ONTA 75mg	Placebo/Placebo	Placebo/ONTA 25mg
Number of subjects	82	11	22
Age Categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	42.3	44.7	40.9
standard deviation	± 14.21	± 14.16	± 9.42
Gender categorical Units: Subjects			
Female	35	5	9
Male	47	6	13
Ethnicity Units: Subjects			
Hispanic or Latino	7	0	3
Not Hispanic or Latino	74	11	19
Not Reported	1	0	0
Unknown	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	1	0	0
Asian	8	1	2
Black or African American	2	0	0
White	69	10	19
Native Hawaiian or Other Pacific Islander	0	0	0

More than one race	0	0	1
Unknown or Not Reported	2	0	0

Reporting group values	Placebo/ONTA 75mg	Total	
Number of subjects	21	366	
Age Categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	39.9 ± 12.10	-	
Gender categorical Units: Subjects			
Female	10	150	
Male	11	216	
Ethnicity Units: Subjects			
Hispanic or Latino	1	27	
Not Hispanic or Latino	20	337	
Not Reported	0	2	
Unknown	0	0	
Race Units: Subjects			
American Indian or Alaska Native	0	4	
Asian	3	28	
Black or African American	1	9	
White	17	312	
Native Hawaiian or Other Pacific Islander	0	1	
More than one race	0	7	
Unknown or Not Reported	0	5	

End points

End points reporting groups

Reporting group title	ONTA 25mg/Placebo
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52 in this study.	
Reporting group title	ONTA 25mg/ONTA 25mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	ONTA 75mg/Placebo
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	ONTA 75mg/ONTA 75mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	Placebo/Placebo
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	Placebo/ONTA 25mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	
Reporting group title	Placebo/ONTA 75mg
Reporting group description: Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52 in this study.	

Primary: Number of Subjects With Remission Based on Composite Score at Week 52

End point title	Number of Subjects With Remission Based on Composite Score at Week 52 ^[1]
End point description: Remission: a composite score of subject reported symptoms using daily e-diary and centrally read endoscopy as follows: stool frequency sub-score 0 or 1 with at least 1-point change from induction study baseline; rectal bleeding sub-score of 0; endoscopic sub-score of 0 or 1 (modified, excludes friability). Composite score consisted of Mayo score without Physician global assessment (PGA) sub-score and ranges from 0-9 points. Mayo score was a measure of UC disease activity ranged from 0-12 points with higher scores= severe disease and consisted of 4 sub-scores, each graded from 0-3. Sub-scores were	

rectal bleeding (range: 0-3, where 0= no blood & 3=blood alone passes), stool frequency (range: 0-3, where 0= normal number of stools and 3=at least 5 stools more than normal), PGA sub-score (range: 0-3- higher score= severe disease), and an endoscopic sub-score (range: 0-3, where 0= normal/inactive disease; 3= severe disease). Analysis: Ontamalimab responder Full Analysis set (FAS).

End point type	Primary
End point timeframe:	
At Week 52	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	6	38	11	33

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.451
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.296
upper limit	0.572

Notes:

[2] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/Placebo v ONTA 75mg/ONTA 75mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.278

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.142
upper limit	0.401

Notes:

[3] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Endoscopic Remission at Week 52

End point title	Number of Subjects With Endoscopic Remission at Week 52 ^[4]
-----------------	--

End point description:

Endoscopic remission was defined by centrally read endoscopic sub-score 0 or 1 (modified, excludes friability). The centrally read endoscopic sub-score of mayo score ranged from 0 to 3, where 0=normal or inactive disease; 3=severe disease (spontaneous bleeding, ulceration). The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	7	40	13	40

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[5]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.463
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.31
upper limit	0.585

Notes:

[5] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/Placebo v ONTA 75mg/ONTA 75mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.339
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.197
upper limit	0.463

Notes:

[6] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Clinical Remission at Week 52

End point title	Number of Subjects With Clinical Remission at Week 52 ^[7]
-----------------	--

End point description:

Clinical remission was defined by stool frequency sub-score of 0 or 1 with at least a 1-point change from induction study baseline in stool frequency sub-score, and rectal bleeding sub-score of 0. Rectal bleeding was assessed on a scale from 0-3, where 0: no blood seen, 1: streaks of blood with stool less than half time, 2: obvious blood or streaks of blood with stool most of the time, and 3: blood alone passes. Stool frequency was assessed on a scale from 0-3, where 0: normal number of stools for this subject, 1: 1 to 2 stools more than normal, 2: 3 to 4 stools more than normal, and 3: 5 or more stools more than normal. Higher scores indicated more severe disease. The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	13	48	19	42

Statistical analyses

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/Placebo v ONTA 75mg/ONTA 75mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.294
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.148
upper limit	0.425

Notes:

[8] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.497
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.337
upper limit	0.62

Notes:

[9] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Sustained Remission at Week 52

End point title	Number of Subjects With Sustained Remission at Week 52 ^[10]
-----------------	--

End point description:

Sustained remission was defined as in remission at Week 52 visit, among Subjects who were in remission at the time of baseline. Remission was defined as a stool frequency sub-score of 0 or 1 with at least a 1-point change from induction study baseline in stool frequency sub-score and rectal bleeding sub-score of 0 and endoscopic sub-score of 0 or 1 (modified, excludes friability). Sub-scores were rectal bleeding (range: 0-3, where 0= no blood & 3=blood alone passes), stool frequency (range: 0-3, where 0= normal number of stools and 3=at least 5 stools more than normal), and an endoscopic sub-score (range: 0-3, where 0= normal/inactive disease; 3= severe disease). The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
End point timeframe:	
At Week 52	

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	4	23	7	22

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[11]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.277
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.129
upper limit	0.398

Notes:

[11] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/ONTA 75mg v ONTA 75mg/Placebo
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.191
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.067
upper limit	0.305

Notes:

[12] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Clinical Response Based on Composite Score at Week 52

End point title	Number of Subjects With Clinical Response Based on Composite Score at Week 52 ^[13]
-----------------	---

End point description:

Clinical response was defined as a decrease from induction study baseline in the composite score of subject reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30%, with an accompanying decrease in the sub-score for rectal bleeding ≥ 1 point or a sub-score for rectal bleeding ≤ 1 . Composite score consisted of Mayo score without the PGA sub-score and ranges from 0 to 9 points. Mayo score was a measure of UC disease activity, ranged from 0-12 points and consisted of 4 sub-scores, each graded from 0-3, higher scores indicating more severe disease. The rectal bleeding sub-scores ranges from 0-3, where 0= no blood & 3=blood alone passes and centrally read endoscopic sub-score ranges from 0-3, where 0= normal/inactive disease; 3= severe disease. Analysis: Ontamalimab responder FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	15	49	20	47

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.488
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.329
upper limit	0.613

Notes:

[14] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/ONTA 75mg v ONTA 75mg/Placebo
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.343
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.194
upper limit	0.471

Notes:

[15] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Mucosal Healing Based on Endoscopic and Histologic Assessment at Week 52

End point title	Number of Subjects With Mucosal Healing Based on Endoscopic and Histologic Assessment at Week 52 ^[16]
-----------------	--

End point description:

Mucosal healing was defined by centrally read endoscopic sub-score 0 or 1 (modified, excludes friability) and centrally read Geboes score of ≤2. The centrally read endoscopic sub-score of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease. The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	6	37	11	29

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[17]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.431
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.28
upper limit	0.554

Notes:

[17] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/ONTA 75mg v ONTA 75mg/Placebo
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.227
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.094
upper limit	0.349

Notes:

[18] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Glucocorticoid-free Clinical Remission at Week 52

End point title	Number of Subjects With Glucocorticoid-free Clinical Remission at Week 52 ^[19]
-----------------	---

End point description:

Glucocorticoid-free clinical remission was defined as clinical remission in addition to not requiring any treatment with glucocorticoids for at least 4 weeks prior to the Week 52 visit among subjects using glucocorticoids at the baseline. Clinical remission was defined as stool frequency sub-score of 0 or 1 with

at least a 1-point change from induction study baseline in stool frequency sub-score, and rectal bleeding sub-score of 0, at the Week 52 visit. The stool frequency sub-score ranges from 0-3, where 0= normal number of stools and 3=at least 5 stools more than normal and rectal bleeding sub-score ranges from 0-3, where 0= no blood & 3=blood alone passes). The ontamalimab responder FAS consisted of all subjects in the randomised set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	1	12	3	12

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[20]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.176
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.049
upper limit	0.287

Notes:

[20] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/ONTA 75mg v ONTA 75mg/Placebo

Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority ^[21]
P-value	< 0.005
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.111
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.006
upper limit	0.208

Notes:

[21] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Glucocorticoid-free Remission at Week 52

End point title	Number of Subjects With Glucocorticoid-free Remission at Week 52 ^[22]
-----------------	--

End point description:

Glucocorticoid-free remission was defined as remission in addition to not requiring any treatment with glucocorticoids for at least 4 weeks prior to the Week 52 visit, among subjects using glucocorticoids at the baseline. Remission was defined as a composite score of subject-reported symptoms using daily e-diary and endoscopy, with stool frequency sub-score of 0 or 1 with at least a 1-point change from induction study baseline, and rectal bleeding sub-score of 0, and endoscopic sub-score of 0 or 1 (modified, excludes friability). Composite score was a recommended measure consisting of the Mayo score without the PGA sub-score and ranges from 0 to 9 points. Stool frequency sub-score, rectal bleeding sub-score and endoscopic sub-score of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Analysis was based on the ontamalimab responder FAS set.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	0	8	2	10

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	ONTA 25mg/Placebo v ONTA 25mg/ONTA 25mg

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[23]
Method	Cochran-Mantel-Haenszel

Notes:

[23] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Statistical analysis title	Statistical Analysis 2
Comparison groups	ONTA 75mg/ONTA 75mg v ONTA 75mg/Placebo
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005 ^[24]
Method	Cochran-Mantel-Haenszel

Notes:

[24] - P-value was based on CMH chi-square test stratified by status of glucocorticoid use at SHP647-303 baseline, prior anti-TNF treatment, and the degree of clinical response in the induction studies (whether remission is achieved or not).

Secondary: Number of Subjects With Clinical Remission Based on Both Rectal Bleeding and Stool Frequency Sub-scores of 0

End point title	Number of Subjects With Clinical Remission Based on Both Rectal Bleeding and Stool Frequency Sub-scores of 0 ^[25]
-----------------	--

End point description:

Clinical remission was defined as both rectal bleeding and stool frequency sub-scores of 0. Rectal bleeding was assessed on a scale from 0-3, where 0: no blood seen, 1: streaks of blood with stool less than half time, 2: obvious blood or streaks of blood with stool most of the time, and 3: blood alone passes. Stool frequency was assessed on a scale from 0-3, where 0: normal number of stools for this subject, 1: 1 to 2 stools more than normal, 2: 3 to 4 stools more than normal, and 3: 5 or more stools more than normal. Higher scores indicated more severe disease. The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects				
At Week 4	28	25	25	24
At Week 8	22	25	29	31
At Week 12	18	26	22	30
At Week 16	16	32	17	35
At Week 20	20	25	16	31

At Week 24	12	31	12	31
At Week 28	13	31	19	32
At Week 32	17	35	13	30
At Week 36	13	37	13	32
At Week 40	15	34	12	25
At Week 44	11	27	12	33
At Week 48	13	32	16	27
At Week 52	9	33	10	30

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Sustained Endoscopic Remission at Week 52

End point title	Number of Subjects With Sustained Endoscopic Remission at Week 52 ^[26]
-----------------	---

End point description:

Sustained endoscopic remission was defined as in endoscopic remission at Week 52 visit among subjects who were in endoscopic remission at the time of baseline. Endoscopic remission was defined as a centrally read endoscopic sub-score of 0 or 1 (modified, excludes friability). The centrally read endoscopic sub-score range from 0 to 3, where 0=normal or inactive disease; 3=severe disease. The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	4	27	8	29

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
-----------------	---

End point description:

An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject

administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs with start dates at the time of or following the first exposure to investigational product. Number of subjects with TEAEs were reported. The safety set consisted of all subjects who had received at least 1 dose of IP in this study, regardless of treatment received during the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
End point timeframe:	
From start of study drug administration up to follow-up (Week 64)	

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	46	41	54	51

End point values	Placebo/Placebo	Placebo/ONTA 25mg	Placebo/ONTA 75mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	22	21	
Units: Subjects	8	11	12	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects who Developed Positive Antidrug Antibodies to Ontamalimab

End point title	Number of Subjects who Developed Positive Antidrug Antibodies to Ontamalimab
-----------------	--

End point description:

Antibody testing was conducted using an electro chemiluminescent signal method. Serum samples was analyzed for presence of antidrug antibodies to ontamalimab. Number of subjects who developed positive results for ontamalimab were reported. The safety set consisted of all subjects who had received at least 1 dose of IP in this study, regardless of treatment received during the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]). Here, "number of subjects analysed" signifies subjects who were evaluable for this endpoint and "n" refers to subjects who were evaluable at specific time points.

End point type	Secondary
End point timeframe:	
At Week 12, 24, 36 and 52	

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	72	70	81	73
Units: subjects				
At Week 12(n=72,70,81,73,11,20,21)	7	6	8	4
At Week 24(n=50,61,63,71,8,22,17)	6	5	5	4
At Week 36(n=34,54,49,67,8,22,15)	5	3	2	4
At Week 52(n=25,53,31,55,7,15,16)	1	2	6	4

End point values	Placebo/Placebo	Placebo/ONTA 25mg	Placebo/ONTA 75mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	22	21	
Units: subjects				
At Week 12(n=72,70,81,73,11,20,21)	2	0	4	
At Week 24(n=50,61,63,71,8,22,17)	1	0	1	
At Week 36(n=34,54,49,67,8,22,15)	2	1	2	
At Week 52(n=25,53,31,55,7,15,16)	1	1	1	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Remission Based on Total Mayo Score at Week 52

End point title	Number of Subjects With Remission Based on Total Mayo Score at Week 52 ^[27]
-----------------	--

End point description:

Remission defined as a total mayo score of ≤ 2 with no individual sub-score (stool frequency, rectal bleeding, endoscopy [modified, excludes friability], and physician's global assessment) exceeding 1. Total mayo score ranges from 0-12 points and consisted of the following 4 sub-scores, each graded from 0-3 with higher scores indicating more severe disease: Sub-scores were rectal bleeding (range: 0-3, where 0=no blood seen and 3=blood alone passes), stool frequency (range: 0-3, where 0=normal number of stools and 3=at least 5 stools more than normal), PGA sub-score (range: 0-3-higher score indicating the severe disease), and an endoscopic sub-score (range: 0-3, where 0=normal or inactive disease; 3=severe disease). The ontamalimab responder FAS consisted of all subjects in the randomized set who received at least 1 dose of IP in this study and who were previously treated with ontamalimab in the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]).

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 52

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As Pre-specified in protocol all efficacy analyses data were collected and analyzed based on ontamalimab responder (i.e ONTA 25mg/ Placebo, ONTA 25mg/ONTA 25mg, ONTA 75mg/Placebo and ONTA 75mg/ONTA 75mg arms only).

End point values	ONTA 25mg/Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo	ONTA 75mg/ONTA 75mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	86	82
Units: Subjects	5	38	10	33

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of study drug administration up to Week 64

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	ONTA 25mg/ Placebo
-----------------------	--------------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Reporting group title	ONTA 25mg/ONTA 25mg
-----------------------	---------------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 25 mg of ontamalimab were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Reporting group title	ONTA 75mg/Placebo
-----------------------	-------------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive placebo (matched to ontamalimab) subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Reporting group title	ONTA 75mg/ONTA 75mg
-----------------------	---------------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with 75 mg of ontamalimab were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Reporting group title	Placebo/Placebo
-----------------------	-----------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive placebo matched to ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Reporting group title	Placebo/ONTA 25mg
-----------------------	-------------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 25 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Reporting group title	Placebo/ONTA 75mg
-----------------------	-------------------

Reporting group description:

Subjects who achieved a clinical response in one of the induction studies (SHP647-301 [2017-000599-27] and SHP647-302 [2017-000572-28]) with placebo were randomised to receive 75 mg of ontamalimab subcutaneously as maintenance treatment using a prefilled syringe once in Q4W up to Week 52.

Serious adverse events	ONTA 25mg/ Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 73 (8.22%)	9 / 71 (12.68%)	9 / 86 (10.47%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Papillary thyroid cancer			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Sudden cardiac death			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Chest discomfort			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic pain			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Uterine polyp			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Nasal septum deviation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis hypertrophic			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Clostridium test positive			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio increased			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Radius fracture			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial infarction			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Facial paralysis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve compression			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient global amnesia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Hypochromic anaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 73 (2.74%)	1 / 71 (1.41%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Bladder metaplasia			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 86 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	ONTA 75mg/ONTA 75mg	Placebo/Placebo	Placebo/ONTA 25mg
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 82 (2.44%)	1 / 11 (9.09%)	0 / 22 (0.00%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Papillary thyroid cancer			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 82 (1.22%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Sudden cardiac death			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic pain			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Nasal septum deviation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis hypertrophic			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Clostridium test positive			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Radius fracture			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial infarction			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	1 / 11 (9.09%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Nervous system disorders			
Facial paralysis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve compression			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient global amnesia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Hypochromic anaemia			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	1 / 11 (9.09%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Bladder metaplasia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 82 (1.22%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	1 / 11 (9.09%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	1 / 11 (9.09%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo/ONTA 75mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 21 (9.52%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Papillary thyroid cancer			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Sudden cardiac death			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 1		
Chest discomfort			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Drug hypersensitivity			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Reproductive system and breast disorders			
Pelvic pain			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine polyp			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 21 (4.76%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Nasal septum deviation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rhinitis hypertrophic			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			

Clostridium test positive alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
International normalised ratio increased alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Injury, poisoning and procedural complications Radius fracture alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Joint injury alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 21 (4.76%) 0 / 1 0 / 0			
Cardiac disorders Myocardial infarction alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Nervous system disorders Facial paralysis alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			

Nerve compression alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Headache alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Transient global amnesia alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Blood and lymphatic system disorders Hypochromic anaemia alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Iron deficiency anaemia alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Gastrointestinal disorders Colitis ulcerative alternative assessment type: Systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 21 (0.00%) 0 / 0 0 / 0			
Large intestine perforation alternative assessment type: Systematic				

subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Bladder metaplasia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Gastroenteritis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infectious colitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonitis			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tracheobronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	ONTA 25mg/ Placebo	ONTA 25mg/ONTA 25mg	ONTA 75mg/Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 73 (56.16%)	27 / 71 (38.03%)	52 / 86 (60.47%)
Investigations			
Weight increased			
alternative assessment type: Systematic			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>White blood cell count decreased</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 73 (0.00%)</p> <p>0</p> <p>0 / 73 (0.00%)</p> <p>0</p>	<p>0 / 71 (0.00%)</p> <p>0</p> <p>0 / 71 (0.00%)</p> <p>0</p>	<p>0 / 86 (0.00%)</p> <p>0</p> <p>0 / 86 (0.00%)</p> <p>0</p>
<p>Injury, poisoning and procedural complications</p> <p>Contusion</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 73 (0.00%)</p> <p>0</p>	<p>0 / 71 (0.00%)</p> <p>0</p>	<p>0 / 86 (0.00%)</p> <p>0</p>
<p>Vascular disorders</p> <p>Hypertension</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 73 (4.11%)</p> <p>3</p>	<p>3 / 71 (4.23%)</p> <p>3</p>	<p>0 / 86 (0.00%)</p> <p>0</p>
<p>Cardiac disorders</p> <p>Arrhythmia</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 73 (0.00%)</p> <p>0</p>	<p>0 / 71 (0.00%)</p> <p>0</p>	<p>0 / 86 (0.00%)</p> <p>0</p>
<p>Nervous system disorders</p> <p>Headache</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 73 (5.48%)</p> <p>5</p>	<p>3 / 71 (4.23%)</p> <p>4</p>	<p>0 / 86 (0.00%)</p> <p>0</p>
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Lymphopenia</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Leukopenia</p>	<p>2 / 73 (2.74%)</p> <p>2</p> <p>0 / 73 (0.00%)</p> <p>0</p>	<p>4 / 71 (5.63%)</p> <p>4</p> <p>0 / 71 (0.00%)</p> <p>0</p>	<p>3 / 86 (3.49%)</p> <p>3</p> <p>0 / 86 (0.00%)</p> <p>0</p>

alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 73 (0.00%) 0	0 / 71 (0.00%) 0	1 / 86 (1.16%) 1
General disorders and administration site conditions Oedema peripheral alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 73 (1.37%) 1	2 / 71 (2.82%) 2	1 / 86 (1.16%) 1
Gastrointestinal disorders Abdominal pain alternative assessment type: Systematic subjects affected / exposed occurrences (all) Colitis ulcerative subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 3 17 / 73 (23.29%) 17	2 / 71 (2.82%) 4 3 / 71 (4.23%) 4	4 / 86 (4.65%) 4 29 / 86 (33.72%) 35
Musculoskeletal and connective tissue disorders Muscle spasms alternative assessment type: Systematic subjects affected / exposed occurrences (all) Arthralgia subjects affected / exposed occurrences (all)	1 / 73 (1.37%) 1 4 / 73 (5.48%) 5	1 / 71 (1.41%) 2 4 / 71 (5.63%) 5	0 / 86 (0.00%) 0 3 / 86 (3.49%) 3
Infections and infestations Corona virus infection alternative assessment type: Systematic subjects affected / exposed occurrences (all) Nasopharyngitis alternative assessment type: Systematic subjects affected / exposed occurrences (all) Respiratory tract infection alternative assessment type: Systematic	0 / 73 (0.00%) 0 4 / 73 (5.48%) 4	0 / 71 (0.00%) 0 3 / 71 (4.23%) 4	1 / 86 (1.16%) 1 3 / 86 (3.49%) 3

subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	2 / 86 (2.33%)
occurrences (all)	1	0	2
Upper respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 73 (1.37%)	1 / 71 (1.41%)	4 / 86 (4.65%)
occurrences (all)	1	1	4
Viral infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 86 (1.16%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Diabetes mellitus			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 86 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	ONTA 75mg/ONTA 75mg	Placebo/Placebo	Placebo/ONTA 25mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 82 (36.59%)	8 / 11 (72.73%)	11 / 22 (50.00%)
Investigations			
Weight increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	1 / 11 (9.09%)	1 / 22 (4.55%)
occurrences (all)	0	1	1
White blood cell count decreased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	0 / 11 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	4
Injury, poisoning and procedural complications			
Contusion			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 82 (0.00%)	1 / 11 (9.09%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			

Hypertension alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 82 (2.44%) 2	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
Cardiac disorders Arrhythmia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 82 (0.00%) 0	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
Nervous system disorders Headache alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 82 (3.66%) 3	1 / 11 (9.09%) 1	3 / 22 (13.64%) 7
Blood and lymphatic system disorders Anaemia alternative assessment type: Systematic subjects affected / exposed occurrences (all) Lymphopenia alternative assessment type: Systematic subjects affected / exposed occurrences (all) Leukopenia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 82 (1.22%) 1 0 / 82 (0.00%) 0 1 / 82 (1.22%) 1	1 / 11 (9.09%) 1 1 / 11 (9.09%) 1 1 / 11 (9.09%) 1	0 / 22 (0.00%) 0 0 / 22 (0.00%) 0 0 / 22 (0.00%) 0
General disorders and administration site conditions Oedema peripheral alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 82 (0.00%) 0	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
Gastrointestinal disorders Abdominal pain alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	3 / 82 (3.66%) 3	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
Colitis ulcerative subjects affected / exposed occurrences (all)	6 / 82 (7.32%) 7	4 / 11 (36.36%) 4	0 / 22 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Muscle spasms alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 82 (0.00%) 0	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	3 / 82 (3.66%) 3	0 / 11 (0.00%) 0	1 / 22 (4.55%) 1
Infections and infestations			
Corona virus infection alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 82 (0.00%) 0	1 / 11 (9.09%) 1	1 / 22 (4.55%) 1
Nasopharyngitis alternative assessment type: Systematic subjects affected / exposed occurrences (all)	6 / 82 (7.32%) 7	2 / 11 (18.18%) 2	1 / 22 (4.55%) 1
Respiratory tract infection alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 82 (2.44%) 2	1 / 11 (9.09%) 1	1 / 22 (4.55%) 1
Upper respiratory tract infection alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 82 (3.66%) 5	0 / 11 (0.00%) 0	2 / 22 (9.09%) 2
Viral infection alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 82 (0.00%) 0	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
Metabolism and nutrition disorders			

Diabetes mellitus alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 82 (0.00%) 0	1 / 11 (9.09%) 1	0 / 22 (0.00%) 0
---	-------------------------	-------------------------	-------------------------

Non-serious adverse events	Placebo/ONTA 75mg		
Total subjects affected by non-serious adverse events subjects affected / exposed	9 / 21 (42.86%)		
Investigations Weight increased alternative assessment type: Systematic subjects affected / exposed occurrences (all) White blood cell count decreased alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0 0 / 21 (0.00%) 0		
Injury, poisoning and procedural complications Contusion alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0		
Vascular disorders Hypertension alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1		
Cardiac disorders Arrhythmia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0		
Nervous system disorders Headache alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1		
Blood and lymphatic system disorders Anaemia alternative assessment type: Systematic subjects affected / exposed occurrences (all) Lymphopenia alternative assessment type: Systematic subjects affected / exposed occurrences (all) Leukopenia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0 0 / 21 (0.00%) 0 0 / 21 (0.00%) 0		
General disorders and administration site conditions Oedema peripheral alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0		
Gastrointestinal disorders Abdominal pain alternative assessment type: Systematic subjects affected / exposed occurrences (all) Colitis ulcerative subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0 1 / 21 (4.76%) 1		
Musculoskeletal and connective tissue disorders Muscle spasms alternative assessment type: Systematic subjects affected / exposed occurrences (all) Arthralgia	0 / 21 (0.00%) 0		

subjects affected / exposed	3 / 21 (14.29%)		
occurrences (all)	4		
Infections and infestations			
Corona virus infection			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 21 (9.52%)		
occurrences (all)	2		
Nasopharyngitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 21 (4.76%)		
occurrences (all)	1		
Respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences (all)	0		
Viral infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Diabetes mellitus			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 21 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 September 2018	Protocol Amendment 1: <ul style="list-style-type: none">- Added a statement to note that subjects who are withdrawn early from the study due to fulfilling the criteria for treatment failure also may be eligible to enter the long-term safety study, SHP647-304.- Added a statement to clarify the timing of the Week 52/ET visit (Visit 14, Part 2) for subjects who fulfilled the criteria for treatment failure and would be entering the long-term safety study.- Added new section describing benefit and risk of SHP647 treatment.- Added pregnancy to the list of reasons a subject may be withdrawn from study treatment.- Added new section describing safety monitoring and stopping algorithms for elevated hepatic blood tests.
11 November 2019	Protocol Amendment 2: <ul style="list-style-type: none">- Updated sample size projections and power considerations to reflect a decrease in the sample size due to a reduction in the targeted power to detect an individual pairwise treatment difference at a highly statistically persuasive level (i.e., a p-value $\leq .001$) in the primary endpoint from 90% to 85% for feasibility reasons.- Updated the text to correctly describe the scoring of subject-reported UC sign and symptom data.- Added text to indicate that adverse events of special interest will be summarized by treatment group.- Added PRO-UC daily e-diary data collection at Visit 14 (Part 2) to reflect that e-diary data were to be collected through Visit 14 (Part 2) to calculate the primary endpoint.- Revised to extend the window between the colonoscopy procedure at Visit 14 (Part 1) and Visit 14 (Part 2) to 10 days, although 5 to 7 days is preferable.- Added new subsection to clarify that infectious etiology must be evaluated when a subject experiences an increase in gastrointestinal symptoms.- Added new subsection to describe classification of hypersensitivity as an adverse event of special interest.- Added language to clarify treatment failure criteria and assessment and reflect that treatment failure could be a reason for subject withdrawal.- Added that oral beclomethasone up to a maximum of 5 mg/day was permitted.
17 September 2020	Protocol Amendment 3: <ul style="list-style-type: none">- Changed the safety follow-up period from 16 weeks to 12 weeks due to the emergent data on the half-life of ontamalimab (16 days).- Added footnote to specify that subjects performing home administrations consecutively for 3 months will need to perform liver function testing locally.- Updated to reflect the discontinuation of ontamalimab Phase 3 clinical development program as follows:<ul style="list-style-type: none">- Specified that the subject's next scheduled visit would be the Week 52/ET visit and clarified the timing of the Week 52/ET visit.- Added language to clarify that, with the early termination of the study by the sponsor, endoscopy was optional for subjects who received less than 52 weeks of treatment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported